GlassScriptPhysician profile
Amit R Vaid
NPI 1558314658
$9,927.04
in general payments reported to CMS, 2019-2025
41 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $371 · 2021: $246 · 2022: $2,500 · 2023: $4,187 · 2024: $609 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Consulting Fee: $2,308 · Education: $175 · Travel and Lodging: $65.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.02 |
| Consulting Fee | $2,307.50 |
| Education | $174.79 |
| Travel and Lodging | $65.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $2,360.21 | 2019-2024 | |
| Glaxosmithkline, LLC. | $866.35 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $818.19 | 2019-2023 | Xolair, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $812.95 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $766.75 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.20 | 2019-2025 | Spiriva Respimat, Jascayd, Ofev |
| Amgen INC. | $367.55 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $363.04 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $300.15 | 2022-2023 | Glassia |
| Insmed, INC. | $266.80 | 2019-2025 | Arikayce |
| Baxter Healthcare | $236.27 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Zoll Respicardia, INC. | $223.82 | 2024 | Remede System |
| Sanofi-Aventis U.S. LLC | $206.44 | 2021-2024 | |
| Mylan Specialty L.P. | $162.19 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $153.53 | 2022-2024 | Prolastin-C Liquid |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Vaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.